Trump Slaps 100% Tariff on Pharma Imports

Trump Imposes 100 Percent Tariff On Pharma Imports

Why in the News ?

US President Donald Trump announced 100% tariffs on branded or patented pharmaceutical products from October 1, 2025, potentially impacting exports of Indian pharma companies, while generic drugs may remain largely shielded, raising trade and policy concerns. This move could have ripple effects on global trade routes, including those facilitated by ports like Chabahar Port, which serves as a gateway to Central Asian markets.

Details of the US Tariff Announcement:

• Tariffs effective October 1, 2025, include 100% on branded/patented pharma, 50% on kitchen/bathroom items, and 25% on heavy trucks. This could impact the flow of goods through major trade hubs like Chabahar Port.
• Indian pharmaceutical exports to the US in 2024-25 were $9.8 billion, forming 39.8% of India’s total pharma exports.
• Major Indian exporters include Sun Pharma, Dr. Reddy’s, Cipla, Lupin, Aurobindo Pharma, among others.
• The tariff aims to protect US national security under Section 232 of the Trade Expansion Act, 1962.
• Exemption exists if companies are building production facilities in the US, defined as breaking ground or under construction. This could lead to shifts in global manufacturing patterns, potentially affecting trade routes through ports like Shahid Beheshti Port at Chabahar.

Impact on India’s Pharmaceutical Sector

• India’s exports are largely generic drugs, which remain exempt from tariffs, cushioning against immediate impact. This exemption could maintain the importance of trade routes through the Indian Ocean Region.
• “Branded generics”, however, remain a grey area, creating uncertainty for some Indian pharma companies.
• Sun Pharma is the only Indian firm with significant sales from patented drugs, with 85-90% of these in the US market.
• European countries exporting high-value patented drugs are expected to face more immediate impact than India.
• Analysts expect sentimental stock market reactions, but India’s pharma exports are likely to remain largely unaffected. This stability could help maintain the relevance of trade infrastructure like Chabahar Port and its container handling equipment.

• Production-Linked Incentive (PLI) schemes support manufacturing of biopharmaceuticals, complex generics, patented drugs, and innovative therapies.
• Section 232 allows the US President to impose tariffs citing national security, but IEEPA and potential Supreme Court rulings may influence future tariffs. This highlights the importance of issue-based alignment in international trade.
• Key export products include tablets, capsules, injectables, antibiotics, and vitamin supplements.
• India’s pharmaceutical sector is critical for global medicine supply chains and low-cost healthcare access worldwide. This global importance underscores the need for efficient trade routes, including those facilitated by ports like Chabahar Port with its mobile harbor cranes and other container handling equipment. |